Esophageal Motility Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major esophageal motility disorders markets are expected to exhibit a CAGR of 5.93% during 2024-2034.
The esophageal motility disorders market has been comprehensively analyzed in IMARC's new report titled "Esophageal Motility Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Esophageal motility disorders (EMDs) encompass a group of medical conditions characterized by abnormal muscle contractions within the esophagus, the narrow passage extending from the mouth to the stomach. These diseases disrupt the coordinated movement of liquids and food from the mouth to the abdomen, leading to a range of symptoms. Common indications of EMDs include dysphagia (difficulty swallowing), chest pain, regurgitation, heartburn, and a sensation of food getting stuck in the throat. These symptoms can substantially impact a patient's quality of life and nutritional intake. The diagnosis of EMDs involves a combination of clinical evaluation, esophageal function tests, and imaging studies. High-resolution manometry is a crucial diagnostic tool that measures pressure changes within the esophageal muscles during swallowing. Additionally, the healthcare provider might recommend imaging techniques like barium swallow studies and esophageal endoscopy to assess structural abnormalities and rule out various other potential causes of underlying symptoms.
The increasing incidences of achalasia, resulting from an autoimmune response that affects the nerves controlling the esophagus, are primarily driving the esophageal motility disorders market. In addition to this, the inflating utilization of minimally invasive procedures, such as endoscopic treatments and peroral endoscopic myotomies (POEM), aimed at rectifying dysfunctional esophageal contractions and restoring normal passage, is also creating a positive outlook for the market. These surgical interventions offer better outcomes with fewer complications, making them increasingly popular among both patients and physicians. Moreover, the widespread adoption of dietary adjustments, coupled with behavioral therapies, for ameliorating EMDs by optimizing swallowing techniques and bolstering muscle coordination is further propelling the market growth. Apart from this, the rising usage of pharmacological interventions like calcium channel blockers, nitrates, and anticholinergic medications to manage symptoms and improve function is acting as another significant growth-inducing factor. Additionally, the growing research in the field of neurogastroenterology to launch targeted therapies that aim to modulate the nervous system's control of esophageal function is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and tissue engineering strategies, which hold the potential to rejuvenate and restore proper esophageal muscle function in individuals suffering from the illness, is expected to drive the esophageal motility disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the esophageal motility disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for esophageal motility disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal motility disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the esophageal motility disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the esophageal motility disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current esophageal motility disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the esophageal motility disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the esophageal motility disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the esophageal motility disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of esophageal motility disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with esophageal motility disorders across the seven major markets?
What is the size of the esophageal motility disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of esophageal motility disorders?
What will be the growth rate of patients across the seven major markets?
Esophageal Motility Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for esophageal motility disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal motility disorders market?
What are the key regulatory events related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by status related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by phase related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by route of administration related to the esophageal motility disorders market?
The esophageal motility disorders market has been comprehensively analyzed in IMARC's new report titled "Esophageal Motility Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Esophageal motility disorders (EMDs) encompass a group of medical conditions characterized by abnormal muscle contractions within the esophagus, the narrow passage extending from the mouth to the stomach. These diseases disrupt the coordinated movement of liquids and food from the mouth to the abdomen, leading to a range of symptoms. Common indications of EMDs include dysphagia (difficulty swallowing), chest pain, regurgitation, heartburn, and a sensation of food getting stuck in the throat. These symptoms can substantially impact a patient's quality of life and nutritional intake. The diagnosis of EMDs involves a combination of clinical evaluation, esophageal function tests, and imaging studies. High-resolution manometry is a crucial diagnostic tool that measures pressure changes within the esophageal muscles during swallowing. Additionally, the healthcare provider might recommend imaging techniques like barium swallow studies and esophageal endoscopy to assess structural abnormalities and rule out various other potential causes of underlying symptoms.
The increasing incidences of achalasia, resulting from an autoimmune response that affects the nerves controlling the esophagus, are primarily driving the esophageal motility disorders market. In addition to this, the inflating utilization of minimally invasive procedures, such as endoscopic treatments and peroral endoscopic myotomies (POEM), aimed at rectifying dysfunctional esophageal contractions and restoring normal passage, is also creating a positive outlook for the market. These surgical interventions offer better outcomes with fewer complications, making them increasingly popular among both patients and physicians. Moreover, the widespread adoption of dietary adjustments, coupled with behavioral therapies, for ameliorating EMDs by optimizing swallowing techniques and bolstering muscle coordination is further propelling the market growth. Apart from this, the rising usage of pharmacological interventions like calcium channel blockers, nitrates, and anticholinergic medications to manage symptoms and improve function is acting as another significant growth-inducing factor. Additionally, the growing research in the field of neurogastroenterology to launch targeted therapies that aim to modulate the nervous system's control of esophageal function is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and tissue engineering strategies, which hold the potential to rejuvenate and restore proper esophageal muscle function in individuals suffering from the illness, is expected to drive the esophageal motility disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the esophageal motility disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for esophageal motility disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal motility disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the esophageal motility disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the esophageal motility disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current esophageal motility disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the esophageal motility disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the esophageal motility disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the esophageal motility disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of esophageal motility disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of esophageal motility disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with esophageal motility disorders across the seven major markets?
What is the size of the esophageal motility disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of esophageal motility disorders?
What will be the growth rate of patients across the seven major markets?
Esophageal Motility Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for esophageal motility disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal motility disorders market?
What are the key regulatory events related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by status related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by phase related to the esophageal motility disorders market?
What is the structure of clinical trial landscape by route of administration related to the esophageal motility disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ESOPHAGEAL MOTILITY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ESOPHAGEAL MOTILITY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ESOPHAGEAL MOTILITY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ESOPHAGEAL MOTILITY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ESOPHAGEAL MOTILITY DISORDERS - UNMET NEEDS
10 ESOPHAGEAL MOTILITY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 ESOPHAGEAL MOTILITY DISORDERS - MARKETED PRODUCTS
11.1 List of Esophageal Motility Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Prilosec (Omeprazol) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Protonix (Pantoprazole) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Reglan (Metoclopramide) - Ani pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ESOPHAGEAL MOTILITY DISORDERS - PIPELINE DRUGS
12.1 List of Esophageal Motility Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ESOPHAGEAL MOTILITY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ESOPHAGEAL MOTILITY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ESOPHAGEAL MOTILITY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Esophageal Motility Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Esophageal Motility Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Esophageal Motility Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Esophageal Motility Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Esophageal Motility Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Esophageal Motility Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Esophageal Motility Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Esophageal Motility Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Esophageal Motility Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Esophageal Motility Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Esophageal Motility Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Esophageal Motility Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Esophageal Motility Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Esophageal Motility Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Esophageal Motility Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Esophageal Motility Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Esophageal Motility Disorders - Access and Reimbursement Overview
16 ESOPHAGEAL MOTILITY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ESOPHAGEAL MOTILITY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ESOPHAGEAL MOTILITY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ESOPHAGEAL MOTILITY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ESOPHAGEAL MOTILITY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ESOPHAGEAL MOTILITY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ESOPHAGEAL MOTILITY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ESOPHAGEAL MOTILITY DISORDERS - UNMET NEEDS
10 ESOPHAGEAL MOTILITY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 ESOPHAGEAL MOTILITY DISORDERS - MARKETED PRODUCTS
11.1 List of Esophageal Motility Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Prilosec (Omeprazol) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Protonix (Pantoprazole) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Reglan (Metoclopramide) - Ani pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ESOPHAGEAL MOTILITY DISORDERS - PIPELINE DRUGS
12.1 List of Esophageal Motility Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ESOPHAGEAL MOTILITY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ESOPHAGEAL MOTILITY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ESOPHAGEAL MOTILITY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Esophageal Motility Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Esophageal Motility Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Esophageal Motility Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Esophageal Motility Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Esophageal Motility Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Esophageal Motility Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Esophageal Motility Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Esophageal Motility Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Esophageal Motility Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Esophageal Motility Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Esophageal Motility Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Esophageal Motility Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Esophageal Motility Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Esophageal Motility Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Esophageal Motility Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Esophageal Motility Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Esophageal Motility Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Esophageal Motility Disorders - Access and Reimbursement Overview
16 ESOPHAGEAL MOTILITY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ESOPHAGEAL MOTILITY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ESOPHAGEAL MOTILITY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
